Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 21, 2009; 15(35): 4429-4433
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4429
Table 1 Patients’ characteristics
VariableNumber of patientsPercentage (%)
Age (yr)
< 406828.3
> 4017271.7
Sex
Female11045.8
Male13054.2
BMI (kg/m2)
< 2813154.5
> 2810945.5
Liver enzymes
Normal11547.9
Abnormal12552.1
PCR (IU/mL)
< 800 00013857.5
> 800 00010242.5
Duration
Completed21589.6
Incomplete2510.4
Side effects
Present12552.1
Absent11547.9
Drug
Peg IFN α-2A13857.5
Peg IFN α-2B10242.5
Genotype
Genotype 14619.2
Genotype 293.8
Genotype 3156.3
Genotype 48234.2
Genotype 510.4
Not identified52.1
No records8234.2
ETVR
Responded16066.7
No response8033.3
SVR
SVR13958.0
No SVR10142.0
Table 2 Overall treatment outcomes
Treatment outcomeFrequency (%)
SVR139 (58)
Relapse17 (7)
Primary non responder61 (25)
Intolerant23 (10)
Total240 (100)
Table 3 Characteristics of patients who achieved an SVR
VariableNumber of patientsSVR (%)P value
Age (yr)
< 4051750.001
> 408851
Sex
Female5752NS
Male8263
BMI (kg/m2)
< 2885650.01
> 285449
PCR (IU/mL)
< 800 00088640.023
> 800 0005150
Drug
Peg IFN α-2A 180 μg/wk8562NS
Peg IFN α-2B 1.5 μg/kg per week5453
Liver enzymes
Normal6960NS
Abnormal7056
Treatment duration
Completed137640.00001
Not completed28